Holding(s) in Company

11 March 2014

Akers Biosciences, Inc.

("ABI" or the "Company")

Holdings in Company

Akers Biosciences, Inc. (AIM:AKR, NASDAQ:AKER), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that the Company was notified on 20 February 2014, that on 7 February 2014, ACT Capital Management, LLP ("ACT") purchased 280,100 common shares of no par value in the Company ("Common Shares") and accordingly now holds 280,100 Common Shares representing 5.7% of the issued share capital of the Company.

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point‐of‐care screening and testing products designed to bring health status information, both rapidly and directly, to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state‐of‐the‐art rapid diagnostic assays can be performed virtually anywhere, in minutes, since time is always of essence. ABI is aligned with high volume medical product distributors to help facilitate the Company's growth into a major, worldwide competitor in the field of rapid diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

Enquiries:

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Antony Legge or James Thomas (Nomad)

Martin Lampshire (Broker)

Daniel Stewart & Company plc

Tel. +44 (0)20 7776 6550

Ben Simons

Vigo Communications

Tel. +44 (0) 20 7016 9574